Answers are grounded in this paper and cite their sources.
The existence of cells expressing stem cell or cancer stem cell markers has been demonstrated and is widely accepted across all subtypes of pituitary neuroendocrine tumors (PitNETs). This observation underscores the potential role and active contribution of a stem cell population to pituitary tumorigenesis. It also raises the question of whether pituitary tumor behavior and the recent identification of plurihormonal PitNETs, may involve or reflect the influence of tumor-associated stem cells with intrinsic capacities for self-renewal or endocrine differentiation. Here, we combined histological, single-cell, and spatial transcriptomic approaches with functional analyses of patient-derived pituispheres to refine our understanding of SOX2-expressing cells in SF1-PitNETs. Our analyses confirm that SOX2⁺ cells are rare and heterogeneously distributed in SF1-PitNETs. We delineate two principal SOX2⁺/SOX9⁺ stem cell populations: one expressing folliculostellate markers (S100B, GFAP, VIM) and the other enriched for canonical cancer stem cell markers (CD133, CD44, CD24). Pseudotime trajectory analysis indicates that CD133⁺/SOX2⁺/SOX9⁺ cells are poised for endocrine differentiation, supported by the identification of transitional cells co-expressing cytoplasm-localized SOX2 and transcription factors of the three major pituitary endocrine lineages. Our results further suggest a potential role for STAT3 signaling in the maintenance and commitment to endocrine differentiation of these tumor-associated cells. These findings support that pituitary tumor behavior is not solely driven by the proliferation of differentiated endocrine cells but may also involve a population of tumor-associated stem cells capable of multilineage differentiation.
No takes yet. Share an insight, caveat, or question.
Flores‐Martínez et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: